Literature DB >> 28762362

Prevalence and pattern of potential drug-drug interactions among chronic kidney disease patients in south-western Nigeria.

J Fasipe Olumuyiwa1, A Akinbodewa Akinwumi2, O Adejumo Ademola2, B Akawa Oluwole1, E Okaka Ibiene3.   

Abstract

BACKGROUND: Management of chronic kidney disease (CKD) patients often requires the use of multiple drugs due to a high number of cardiovascular risk factors and complications associated with the disease. Multiple drugs predispose to potential drug-drug interactions (DDIs) which may be associated with increased morbidity, mortality, length of hospital stay and health-care cost.
OBJECTIVES: This study determined the prevalence and pattern of potential DDIs among CKD patients attending Kidney Care Centre, in Ondo City, Nigeria.
METHODOLOGY: It was an 18-month retrospective study that involved the reviewed CKD patients' records. The Lexi-Interact database was used to evaluate patients' medications for potential DDIs.
RESULTS: One hundred and twenty-three (123) CKD patients, made up of 82 (66.67%) males and 41 (33.33%) females were studied. The mean age of the CKD patients was 53.81 ± 16.03 years. The most common comorbid conditions were hypertension in 103 (83.74%) and diabetes mellitus in 39 (31.71%). A total of 1237 prescriptions were made and the mean number of prescribed medications per patient was 10.06 ± 3.97. A total number of 1851 potential DDIs were observed among 118 patients. The prevalence of potential DDIs was 95.9% while the mean DDIs per prescription was 1.27. Among the potential DDIs observed, the severity was mild in 639 (34.5%), moderate in 1160 (62.7%), major in 51 (2.8%) and only 1 (0.1%) was of avoid drug combination. The most frequent DDI was between calcium carbonate and oral ferrous sulphate.
CONCLUSION: The prevalence of potential DDIs is high among CKD patients. About 63% of these interactions have moderate severity. Clinicians and pharmacists should utilise available DDI software to avoid harmful DDIs in CKD patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28762362     DOI: 10.4103/npmj.npmj_64_17

Source DB:  PubMed          Journal:  Niger Postgrad Med J


  8 in total

1.  Prevalence of Potential Pharmacological Interactions in Patients Undergoing Systemic Chemotherapy in a Tertiary Hospital.

Authors:  Eric Diego Turossi-Amorim; Bruna Camargo; Fabiana Schuelter-Trevisol
Journal:  Hosp Pharm       Date:  2022-04-02

2.  Potential Drug-Drug Interactions in Patients With Urinary Tract Infections: A Contributing Factor in Patient and Medication Safety.

Authors:  Sidra Noor; Mohammad Ismail; Fahadullah Khan
Journal:  Front Pharmacol       Date:  2019-09-17       Impact factor: 5.810

3.  Drug-Related Problems and Associated Factors among Patients Admitted with Chronic Kidney Disease at Jimma University Medical Center, Jimma Zone, Jimma, Southwest Ethiopia: A Hospital-Based Prospective Observational Study.

Authors:  Aster Wakjira Garedow; Eshetu Mulisa Bobasa; Amare Desalegn Wolide; Fantu Kerga Dibaba; Fanta Gashe Fufa; Birtukan Idilu Tufa; Serkadis Debalke; Kabaye Kumela Goro
Journal:  Int J Nephrol       Date:  2019-10-20

4.  Potential Drug-drug Interactions in Acute Ischemic Stroke Patients at the Neurological Intensive Care Unit.

Authors:  Dejan Z Aleksic; Slobodan M Jankovic; Milos N Mlosavljevic; Gordana L Toncev; Svetlana D Miletic Drakulic; Srdjan M Stefanovic
Journal:  Open Med (Wars)       Date:  2019-11-07

Review 5.  Drug-drug interactions in polypharmacy patients: The impact of renal impairment.

Authors:  Bianca Papotti; Cinzia Marchi; Maria Pia Adorni; Francesco Potì
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-03-29

6.  The Prevalence of Potential Drug-Drug Interactions in CKD-A Retrospective Observational Study of Cerrahpasa Nephrology Unit.

Authors:  Andleeb Shahzadi; Ikbal Sonmez; Cagla Kose; Burhaneddin Oktan; Selma Alagoz; Haktan Sonmez; Adil Hussain; Ahmet Gokhan Akkan
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

7.  Potential drug interactions in adults living in the Brazilian Amazon: A population-based case-control study, 2019.

Authors:  Tayanny Margarida Menezes Almeida Biase; Marcus Tolentino Silva; Tais Freire Galvao
Journal:  Explor Res Clin Soc Pharm       Date:  2021-08-12

8.  Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.

Authors:  Yemi R Raji; Samuel O Ajayi; Abiodun M Adeoye; Olukemi Amodu; Bamidele O Tayo; Babatunde L Salako
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.